Susceptibility to voriconazole, fluconazole, and ketoconazole of yeast isolated from Patients with hematological malignancies

Journal of Chemotherapy

Volumn 20, Issue 6, 2008, Pages 758-760

  Nawrot, Urszula ^a   Nowicka, J ^a   Wlodarczyk, K ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ACUTE LEUKEMIA; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDIASIS; FECES ANALYSIS; FUNGUS GROWTH; FUNGUS ISOLATION; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; SPUTUM ANALYSIS;

EID: 59349088230     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.6.758     Document Type: Article

References (14)

1. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006; 57(4): 628-38.
2. Castagnola E, Machetti M, Bucci B, Viscoli C. Antifungal prophylaxis with azole dervatives. Clin Microbiol Infect, 2004; 10 (Suppl.1): 86-95.
3. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91(8): 1068-1075.
4. Tortorano AM, Kibbler C, Pemanc J, Bernhardt H, Klingspor L, Grillot L. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrobial Agents 2006; 27(5): 359-366.
5. Clinical Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, vol. M27-A2:. CLSI, Wayne, Pa.
6. Maxwell MJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Diekema DJ, et al. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol. 2003; 41(3):1087-90.
7. MedCalc for Windows, Statistics for Biomedical Research, Software Manual. Version 8.1. Mariakerke, Belgium: MedCalc Software
8. Nawrot U, Nowicka J, Juszczak K, Gusin B. Susceptibility to antifungal agents of Candida species isolated from paediatric and adult patients with haematological diseases. Mycoses 2005, 48(6), 385-390.
9. Cartledge JD, Midgley J, Gazzard BG. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS. 1997; 11(15): 1839-44.
10. Candido RC, Toloi MR, Franceschini SA, Garcia FR, Minto EC. In vitro activity of antimycotic agents determined by E-test method against vaginal Candida species. Mycopathologia. 1999; 144(1): 15-20.
11. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44(2): 529-535.
12. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods. J Clin Microbiol. 2007; 45(1): 70-75.
13. Panackal AA, Gribskov JL, Staab JF, Mrby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol. 2006; 44(5):1740-3.
14. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol. 2004; 42(7): 3137-41.